LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a hold rating to a buy rating in a report issued on Tuesday morning, Zacks.com reports. They currently have $33.00 price objective on the medical instruments supplier’s stock.

According to Zacks, “LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “

Several other equities research analysts also recently commented on the stock. Barrington Research reiterated a buy rating and set a $38.00 price objective on shares of LeMaitre Vascular in a research note on Friday, February 7th. ValuEngine downgraded shares of LeMaitre Vascular from a hold rating to a sell rating in a research note on Friday, February 7th. Lake Street Capital upgraded shares of LeMaitre Vascular from a hold rating to a buy rating and set a $40.00 price objective for the company in a research note on Thursday, October 24th. BidaskClub downgraded shares of LeMaitre Vascular from a buy rating to a hold rating in a research note on Friday, January 17th. Finally, First Analysis downgraded shares of LeMaitre Vascular from a strong-buy rating to an outperform rating and lifted their price objective for the stock from $37.00 to $40.00 in a research note on Thursday, October 24th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $37.75.

NASDAQ LMAT opened at $30.11 on Tuesday. The firm’s fifty day simple moving average is $35.44 and its two-hundred day simple moving average is $34.14. LeMaitre Vascular has a 12-month low of $24.94 and a 12-month high of $38.64. The firm has a market capitalization of $601.93 million, a P/E ratio of 34.22, a P/E/G ratio of 3.63 and a beta of 1.23.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.23. LeMaitre Vascular had a net margin of 15.30% and a return on equity of 12.85%. The business had revenue of $30.20 million for the quarter, compared to analyst estimates of $30.44 million. During the same period in the previous year, the company earned $0.30 earnings per share. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. On average, analysts forecast that LeMaitre Vascular will post 0.94 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, March 3rd will be paid a dividend of $0.095 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.09. This represents a $0.38 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Monday, March 2nd. LeMaitre Vascular’s payout ratio is presently 38.64%.

In related news, CFO Joseph P. Pellegrino, Jr. sold 25,945 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $35.09, for a total transaction of $910,410.05. Following the completion of the transaction, the chief financial officer now directly owns 184,054 shares in the company, valued at $6,458,454.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Joseph P. Pellegrino, Jr. sold 121,159 shares of the business’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $34.93, for a total transaction of $4,232,083.87. Insiders have sold 332,239 shares of company stock valued at $11,824,710 over the last quarter. Insiders own 19.60% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. grew its stake in LeMaitre Vascular by 311.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 82,717 shares of the medical instruments supplier’s stock valued at $2,974,000 after acquiring an additional 62,623 shares in the last quarter. UBS Group AG boosted its holdings in LeMaitre Vascular by 40.3% in the 4th quarter. UBS Group AG now owns 19,271 shares of the medical instruments supplier’s stock valued at $693,000 after purchasing an additional 5,531 shares during the last quarter. Amundi Pioneer Asset Management Inc. boosted its holdings in LeMaitre Vascular by 5.4% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 163,194 shares of the medical instruments supplier’s stock valued at $5,862,000 after purchasing an additional 8,305 shares during the last quarter. Capital Impact Advisors LLC boosted its holdings in LeMaitre Vascular by 5.6% in the 4th quarter. Capital Impact Advisors LLC now owns 62,055 shares of the medical instruments supplier’s stock valued at $2,231,000 after purchasing an additional 3,297 shares during the last quarter. Finally, Stifel Financial Corp acquired a new position in LeMaitre Vascular in the 4th quarter valued at about $222,000. Institutional investors own 79.54% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Recommended Story: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.